Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | IDE | P14735 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 6/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035650 | 0.90 | PLA2G4B (0.39) | NR1H2NR1H3RXRAEGLN1IDE | |
| SCHEMBL6036389 | 0.89 | NR1H2 (0.44) | NR1H2NR1H3RXRAEGLN1PTGDR2 | |
| SCHEMBL6036203 | 0.88 | NR1H2 (0.43) | NR1H2NR1H3RXRAEGLN1PTGDR2 | |
| SCHEMBL6218738 | 0.86 | SMN1; SMN2 (0.44) | EGLN1IDESMN1; SMN2MAOB | |
| SCHEMBL6035801 | 0.85 | PPARD (0.45) | EGLN1IDESMN1; SMN2PPARDPPARA | |
| SCHEMBL6036208 | 0.84 | DGAT1 (0.41) | NR1H2NR1H3RXRAEGLN1PTGDR2 | |
| SCHEMBL6034690 | 0.83 | PPARD (0.48) | PTGDR2SMN1; SMN2PPARDPPARAPPARG | |
| SCHEMBL6035924 | 0.82 | SMN1; SMN2 (0.39) | NR1H2NR1H3RXRAEGLN1IDE | |
| SCHEMBL6035082 | 0.81 | PPARD (0.52) | NR1H2NR1H3RXRAPTGDR2PPARD | |
| SCHEMBL6035959 | 0.81 | PLA2G4B (0.42) | NR1H2NR1H3RXRAEGLN1IDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | NR1H2 12/4885NR1H3 4/4885RXRA 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.